The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Jaguar's rebrand has been criticized as 'woke.' Marketing experts say it's either 'bonkers' — or a genius disruption.

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Patients who have a family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome Type 2 are not ...

While avoiding weight gain has long been considered a matter of personal willpower, the rise of "food noise" shows New Year's resolutions are never enough.

The U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.